EU approves COVID-19 vaccine of Novovax company

The European Medicines Agency (EMA) has recommended the issuance of an interim marketing authorization for the Nuvaxovid coronavirus vaccine, produced by the American biotechnology company Novavax.

Report informs referring to the EMA that the efficiency of the drug is about 90%, at least against the strains "alpha" and "beta", which were the most common at the time of the research.

The vaccine is intended for people over the age of 18.

The most common side effects of the drug are pain at the injection site, fatigue, muscle and joint pain, headache, and nausea. Symptoms are mild to moderate and resolve within a few days after vaccination. The final step to open up the possibility of using the vaccine in the EU is to be approved by the European Commission.

Four vaccines have been approved for use in the EU: Spikevax by the American company Moderna, Comirnaty by the American company Pfizer and its German partner BioNTech, Vaxzevria by the British-Swedish company AstraZeneca, and the vaccine by Janssen, owned by the American corporation Johnson & Johnson.